Sarepta Therapeutics (SRPT) Gross Profit (2017 - 2026)

Sarepta Therapeutics' Gross Profit history runs 10 years deep, the most recent figure standing at $622.0 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 14801.84% year-over-year to $622.0 million in Q1 2026; TTM through Mar 2026 was $1.4 billion, a 12.97% increase from a year earlier, with the FY2025 full-year figure at $1.0 billion, down 35.26% from the prior year.
• Gross Profit improved to $622.0 million in Q1 2026 per SRPT's latest filing, from $44.2 million in the prior quarter.
• Across five years, Gross Profit topped out at $1.0 billion in Q4 2023 and bottomed at -$4.2 million in Q1 2025.
• The 5-year median for Gross Profit is $272.3 million (2023), against an average of $355.2 million.
• Across the five-year window, Gross Profit jumped 20154.48% in 2022 and tumbled 101.17% in 2025, its largest moves.
• Year by year, Gross Profit stood at $835.5 million in 2022, then increased by 23.76% to $1.0 billion in 2023, then sank by 49.12% to $526.1 million in 2024, then sank by 91.59% to $44.2 million in 2025, then jumped by 1306.49% to $622.0 million in 2026.
• Per Business Quant, the three latest SRPT Gross Profit figures stand at $622.0 million (Q1 2026), $44.2 million (Q4 2025), and $248.6 million (Q3 2025).